The review analyzes the current biomarkers used in monitoring pancreas transplant, from the simple and time-tested, to more sophisticated, including markers of allo-and autoimmunity, that are likely to play a larger role in future studies.
INTRODUCTION
Whole organ pancreas transplant combined with kidney transplant, has become the therapy of choice for patients with type I diabetes (T1D) and end-stage renal disease [1] . The pancreas transplantion restores euglycemia, without the need for exogenous insulin. The benefit of pancreas transplantion is particularly felt by those patients with long-standing T1D who reach the point of reduced hypoglycemia awareness. Recently, benefit has also been demonstrated in those patients with evidence of C-peptide secretion prior to transplant, that is, patients with type 2 diabetes [2, 3] . As the pancreas transplant is performed for its endocrine effect, that is, restoration of euglycemia/C-peptide secretion, patients are monitored for hemoglobin A1c, glucose, and C-peptide levels. In addition pancreas exocrine markers, including serum levels of amylase and lipase, are followed as they offer further evidence of pancreas transplant health and are often the harbingers of pancreas transplant rejection, occurring prior to a detectable change in glycemic control. For those instances where the pancreas and duodenum are drained into the bladder, urine amylase may also be a useful marker of pancreas transplant function.
Beyond the basic endocrine and exocrine markers of the pancreas transplant, there are important biomarkers that have begun to assume a larger role in the monitoring of pancreas transplant function. These include markers of allo-and autoimmunity. The pancreas is relatively unique among solid organ transplant in that it is subject to both alloimmunity and autoimmunity. The alloimmune response to pancreas transplantion includes both cellular and humoral rejection. The autoimmune response involves recurrence of autoimmunity and is assessed by following levels of autoantibodies and autoreactive T cells. Ultimately for both alloand autoimmune responses, a pancreas transplant biopsy provides the necessary information for definitive diagnosis. As restoration of glycemic control takes years to have a significant biological impact, as demonstrated in the DCCT study series [4, 5] and David Sutherland's studies of pancreas transplantion effects on native kidney histology [6, 7] , evaluation of biomarkers that may prolong pancreas transplantion graft survival, is critically important to this field.
THE ALLOIMMUNE RESPONSE
After revascularization of the pancreas transplant, the blood glucose will begin to fall to normal levels in the operating room. The serum amylase and lipase will rise for the first 48 h and then fall to normal values over the ensuing days as the pancreas transplant recovers from the ischemia/reperfusion injury. In those cases of bladder drainage, the urine amylase will start to increase after 48 h, measured as units of amylase per hour, and eventually peak in a range that is relatively consistent for each pancreas transplant recipient. A subsequent rise in serum amylase/lipase, depending on how long after transplant, will prompt an imaging study (ultrasound, or computed tomography of the abdomen and pelvis) to rule out a surgical complication, for example, duodenal leak. If there is no evidence of pancreas transplantion complication, then acute rejection is considered likely. For bladder drained pancreas transplantion, the urine amylase is assessed and typically the bladder is decompressed with a Foley catheter. If the serum amylase/lipase returns normal and the urine amylase returns to baseline [8] , the hyperamylasemia is ascribed to bladder distention which can be managed by adjusting voiding habits. Recently, the monitoring of urine amylase to urine creatinine ratio has been demonstrated to be as effective as the measurement of urine amylase in terms of units per hour [8] . If the urine amylase does not return to baseline, or for intestinal drained pancreas transplant, if the serum amylase /lipase remain elevated, the pancreas transplant recipient may be treated empirically with steroids and/or undergo a pancreas transplant biopsy. For those pancreas transplant with bladder drainage, if the urine amylase returns to baseline and the serum amylase/lipase return to normal after empiric steroid therapy then this is regarded as a steroid responsive, mild acute rejection episode. Otherwise the pancreas transplant biopsy interpretation will direct the next level of therapy [9] .
Cell-mediated rejection seen on pancreas transplant biopsy may be treated with steroids or for more severe rejection thymoglobulin. In the case of humoral or mixed cellular rejection, C4d is identified on biopsy and accompanied by donor-specific antibody (DSA) in the serum of the pancreas transplant recipient. DSA may be de novo or persistent, if present from before the pancreas transplantion. Although DSA is a hallmark of worse outcome in the kidney transplant [10] , it is less clear in the context of pancreas transplantion [11] . There are studies correlating DSA with pancreas transplant graft failure but either de-novo DSA was not distinguished from preformed consistently [12] or pancreas transplantion graft loss was not correlated with TP biopsy results [13] . Thus, DSA remains an attractive biomarker before and after pancreas transplantion, necessary to assess and to better understand the development of the alloimmune humoral response [11, 14] .
AUTOIMMUNITY FOLLOWING PANCREAS TRANSPLANT
The first study of autoimmunity after pancreas transplant was from Sutherland et al. [15] when he performed living donor pancreas transplantion in twins or HLA identical siblings who received no or minimal immunosuppression [16] . This observation lent support to the concept that T1D was an KEY POINTS Sudden onset of hyperglycemia (DKA) years after SPK transplant, in the context of persistent urine amylase (bladder-drained pancreas transplant) and stable kidney transplant function, should alert to the possibility of recurrent autoimmunity.
T1DR is most often preceded by a rise in levels of autoantibodies (GAD65, IA-2, and ZnT8), particularly levels of ZnT8 close to the event, and the greater the number of elevated autoantibodies the higher the likelihood of developing T1DR.
Genetic risk factors for T1DR include recipient HLA-DR3 and HLA-DR4, as well as donor-recipient sharing of HLA-DR3.
T1DR is characterized by the following: pancreas transplant biopsy that shows insulitis, elevated serum autoantibodies, and autoreactive T cells in the blood, pancreas transplant, and peripancreas transplant tissues.
Despite numerous attempts to treat T1DR with various types of immunosuppression, similar to efforts to treat newly diagnosed T1D, none has yet proven to be effective.
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autoimmune disease. There have been other studies of recurrence of T1D [type 1 diabetes recurrence (T1DR)] identified in the explants of pancreas transplant from deceased donors [17] . However, it is felt that immunosuppression sufficient to prevent rejection is also capable of preventing recurrence of autoimmunity [18] and so T1DR has been considered a relatively rare event. In Fig. 1 , we show an example of an islet from a pancreas transplant of an simultaneous pancreas-kidney (SPK) transplant recipient who developed T1DR. This is notable for the presence of a significant CD3 T cell infiltrate (insulitis), as well as insulin staining of residual islet/ b cells, although there is evidence of b cell loss.
IDENTIFICATION OF AUTOANTIBODIES AND AUTOREACTIVE T CELLS IN PATIENTS WITH TYPE 1 DIABETES RECURRENCE
We began studying T1DR in our SPK transplant recipients in 2003 when we identified our first such patient. Most (95%) of our pancreas transplantion are performed in the context of SPK transplant, and nearly all involve bladder drainage of the pancreasduodenal transplant [1] . This patient presented with severe, abrupt hyperglycemia [diabetic ketoacidosis (DKA)] about 5 years after SPK transplant, during which time the patient had been normoglycemic with no exogenous insulin required. The kidney function was unchanged/normal and urine amylase was stable and consistent. The patient underwent biopsy of both kidney and pancreas and was found to have normal kidney biopsy (no rejection), while the pancreas biopsy showed insulitis with CD3 þ , CD4 þ , CD8 þ , and CD20 þ infiltrates as well as the presence of insulin staining in the b cells. We evaluated stored sera for levels of autoantibodies, specifically GAD65 and IA-2, and noted autoantibody conversion of both autoantibodies prior to developing hyperglycemia. GAD65-specific autoreactive T cells were also identified in the peripheral blood of this patient. In addition to insulin staining present on pancreas transplant biopsy, this patient also continued to have detectable C-peptide levels in the peripheral blood. In view of this, it was felt that there was potential for therapeutic intervention and possible salvage of the pancreas transplant function. This patient received a course of thymoglobulin and anti-CD25 mAb (daclizumab) with resultant transient increase in fasting C-peptide and loss of GAD65specific autoreactive T cells from the peripheral blood. However, a year later the GAD65-autoreactive T cells were again found in the peripheral blood. Subsequently, the C-peptide levels fell, and pancreas transplant function was lost [19] .
Our experience in caring for patients with T1DR continued with a second patient who developed hyperglycemia 9 and a half years after SPK transplant. Hyperglycemia (DKA) occurred in the context of autoantibody conversion of both GAD65 and IA-2 autoantibodies. A pancreas transplant biopsy was performed on which insulitis and the typical predominance of CD8 þ T cells were identified along with some degree of b cell loss, however, insulin staining was preserved in many islets. Autoreactive CD8 þ T cells were identified in the peripheral blood directed against the autoantigen IGRP. A combination of therapies including thymoglobulin, monoclonal anti-CD25 antibody (daclizumab), and a single dose of rituximab were used. This resulted in reduction of autoreactive T cells below the level of detection that persisted for approximately 1 year. Initially, fasting C-peptide levels increased after this treatment, however, autoreactive T cells returned to the peripheral blood and Cpeptide secretion was lost [19] .
In most of our experience, patients who present hyperglycemic (DKA) after SPK transplant still secrete residual amounts of C-peptide in their peripheral blood and insulin staining b cells are identifiable on the pancreas transplant biopsy [20] . This allows us to justify treatment with immunotherapy in an attempt to preserve C-peptide secretion. However, we have also identified a small number of patients who return with severe hyperglycemia after SPK transplant in whom no C-peptide secretion is This shows an islet cell stained for insulin (brown), and CD3 (red). There is a CD3 infiltrate (insulitis) and persistent insulin staining, although there is evidence of b cell loss (magnification Â50). T1DR, type 1 diabetes recurrence.
identified in the peripheral blood and on biopsy of the pancreas transplant, show no evidence of insulin staining. These patients have been treated with retransplantation of the pancreas.
One specific example involves a patient who was diagnosed with hyperglycemia 5 years after SPK transplant, who experienced conversion of autoantibodies including GAD65, and ZnT8 3 months prior to clinical development of hyperglycemia. This patient received a second pancreas transplant. During retransplant surgery peripancreatic transplant tissue was resected in addition to a portion of the tail of the initial pancreas transplant for surgical reasons, specifically, enabling access to the external iliac artery and vein for perfusion of the second pancreas transplant. Autoreactive GAD65-specific CD4 þ T cells were identified in the peripheral blood. In addition, autoreactive GAD65-specific T cells were identified in the initial pancreas transplant as well as in the peripancreatic transplant tissues [19] . This patient received thymoglobulin, daclizumab, one dose of rituximab, plasmapheresis, and intravenous immunoglobulin for therapy at the time of second pancreas transplant. Euglycemia persisted for 3 years during which time GAD65-specific autoreactive CD4 þ T cells could not be detected in the peripheral blood. However, GAD65 autoantibodies and GAD65-specific autoreactive CD4 þ T cells were identified once again 3 years after the second pancreas transplant in the peripheral blood. After this point C-peptide levels fell and were no longer detectable. Biopsy of the second pancreas transplant was performed that revealed a remarkably fibrotic pancreas transplant residual which had undergone rejection and fibrosis. We hypothesize that the autoimmune response may have been a factor in triggering rejection in this aggressively attacked fibrotic residual of pancreas transplant [19] .
POTENTIAL ROLE OF MEMORY T CELLS IN TYPE 1 DIABETES RECURRENCE
Of note, in the previously described patient, GAD65specific autoreactive CD4 þ T cells had been detected with the same CDR3 and Vb expression from the peripheral blood at the time of T1DR observation in the first transplant that persisted after loss of the second pancreas transplant. This is consistent with a memory T-cell response that is resistant to conventional immunosuppression. This patient's course raises the concept that, in the event of retransplantation for an SPK transplant recipient with T1DR, the previous pancreas transplant and peripancreatic transplant tissues which include lymph nodes, should be excised, as they may be harboring autoreactive, memory T cells. Removal of these autoreactive, memory T cell-containing tissues, may provide protection from T1DR [19] .
Another example of an SPK transplant recipient who developed T1DR provides further justification for following biomarkers including autoantibodies and autoreactive T cells, and specifically markers of T cell memory function. This patient presented with hyperglycemia 9 years after SPK transplant. Conversion for GAD65, IA-2, and ZnT8 autoantibodies occurred years prior to clinical hyperglycemia. Biopsy of the pancreas transplant demonstrated autoreactive T cells with insulitis and reduced insulin staining although some insulin staining of b cells persisted. Infiltrating T cells predominantly expressed CD45RO, a marker of T cell memory. These T cells also stained positive for CD2. In the peripheral blood and in the peripancreatic transplant lymph nodes GAD65 autoreactive CD8 cells, the majority of which was memory T cells lacking surface expression of CCR7 (suggesting an effector memory phenotype) were identified. In view of evidence for T cell staining for CD2, we treated this patient with alefacept (a mAb to CD2) [21] . Alefacept has been used to treat patients with psoriasis and targets memory lymphocytes [22] . Interestingly, alefacept has also been used in a clinical trial for patients recently diagnosed with T1D. In this study, in which patients were given two 3-month courses of alefacept, C-peptide secretion appeared to be preserved for up to 2 years [23 & ,24]. Our patient received one 3-month course of alefacept during which time there was a remarkable fall in the frequency of circulating GAD65 and IGRP autoreactive memory CD8 T cells in the peripheral blood suggesting that alefacept had been effective from an immunologic perspective [25] . However, alefacept was withdrawn from the market, and so we were unable to administer a second course of therapy which perhaps may have been successful. This patient experienced the return of memory autoreactive T cells, and has remained insulin dependent.
EFFECTS OF AUTOREACTIVE T CELLS IN EXPERIMENTAL IN-VIVO MODEL
Emphasizing the potential importance of autoreactive T cells as biomarkers, we studied the effect of CD4 þ autoreactive T cells that were specific for GAD65 that had been obtained from two patients with T1DR, and placed them under the kidney capsule of immunodeficient (nude) mice along with human islet cells [19] . Other mice received islet grafts alone or islet grafts and irrelevant T cells from these two patients. The kidneys were removed 1-2 weeks later, and the grafts were examined. Control mice demonstrated normal islet cell histology and insulin staining. Grafts that received human islets and GAD65 autoreactive CD4 þ T cells showed severe islet destruction and loss of insulin staining. In one instance where the mice were rendered diabetic after therapy with streptozotocin before transplant, those mice transplanted with human islets alone or islets with the irrelevant T cells became euglycemic. However, mice that received islets along with GAD65 autoreactive CD4 þ T cells did not reverse their diabetes. This provided a functional correlation of the pathologic evaluation of these grafts. This study showed the potential for human GAD65 autoreactive CD4 þ T cells to mediate destruction of human islet cells in vivo [19] .
ASSESSMENT OF AUTOANTIBODIES IN MIAMI PANCREAS TRANSPLANT COHORT
In our experience with SPK transplant that began in 1990 and has extended for over 25 years, we have measured T1D-associated autoantibodies to GAD65, IA-2, and ZnT8 in serum samples that were collected longitudinally. Autoreactive T cells have been assessed in the peripheral blood and when possible in the pancreas transplant and in the peripancreatic transplant lymph nodes using tetramer technology [19, 25] . We recently completed a retrospective analysis of 223 SPK transplant recipients. In this study, 17 patients (7.6%) were classified as having developed T1DR, 4.5% were categorized as having pancreas transplant chronic rejection and 9% as undetermined, since there was no apparent single cause for the hyperglycemia. Generally, these latter patients had mild symptoms of diabetes, did not require insulin therapy, had evidence of persistent insulin secretion and were often overweight or obese lacking clear signs of rejection. Importantly, in our cohort, T1DR appears to occur no less frequently than pancreas transplant chronic rejection, suggesting that monitoring of biomarkers of autoimmunity may serve a useful purpose.
Approximately, 60% of our SPK recipients were classified as autoantibody negative at the time of transplant, and 40% tested positive for autoantibodies [26 && ]. The presence of autoantibodies pretransplant did not have an impact on outcome. Approximate 25% of our patients were classified as having autoantibody conversion, that is, they were autoantibody negative pretransplant and became autoantibody positive on follow-up or they were positive for a specific autoantibody pretransplant and later acquired positivity for other autoantibodies. Multiple autoantibodies are a risk factor for the development of T1D in relatives [27] . Similar to the development of T1D in the native pancreas, autoantibodies are a risk factor for disease recurrence in the transplanted pancreas [26 && ]. Patients who developed T1DR had higher HG.T1DR free survival 15 20 Years from TX HG.T1DR free survival 15 20 Years from TX HG.T1DR free survival 15 20 Years from TX 25 Autoantibody number prevalence of all antibodies after pancreas transplantion ( Fig. 2) . Importantly, autoantibody positivity and multiple antibodies are associated with an increased risk of T1DR. The presence of three autoantibodies was associated with development of T1DR over 10 years in almost every instance. Furthermore, autoantibody conversion but not autoantibody persistence is a significant risk factor for T1DR ( Fig. 2) . Of further note, the appearance of autoantibodies to ZnT8 was followed by hyperglycemia within an average of 6 months. Consistent with the genetic predisposition to islet autoimmunity and T1D, SPK recipients with T1DR carried the high-risk HLA-DR 3/DR4 heterozygous genotype twice as often as SPK recipients that were normoglycemic. Similarly, they shared HLA-DR alleles with their donors at an increased frequency. Finally, carrying HLA-DR 3/DR4 genotype and sharing HLA-DR alleles with the donor were associated with autoantibody conversion [26 && ].
CONCLUSION
In this review of biomarkers of pancreas transplant, both allo-and autoimmunity have been discussed. In our series of SPKT recipients who have developed T1DR, we have analyzed the cardinal features of autoimmune T1D, which have now been highlighted as the critical autoimmune biomarkers for pancreas transplant. These include autoantibodies, autoreactive T cells, and pancreas transplant biopsies (in which we have also demonstrated autoreactive T cells). Our effort has also been incorporated into the nPOD (network of Pancreas Organ Donors with Diabetes) program as nPOD-transplant [28,29 && ]. We anticipate that further work focused on pancreatic tissue-targeted research will lead to new therapeutic approaches to both T1DR and newly diagnosed T1D.
